Swiss pharmaceutical company Roche announced on September 1 that it will launch a new rapid detection method for coronavirus in Europe by the end of this month, according to the website of consumer news and business channel of the United States. The company said the antigen test will be used in immediate detection scenarios for asymptomatic and symptomatic patients. It’s usually within 15 minutes.
said that novel coronavirus pneumonia patients were more than 96% sensitive to the diagnostic accuracy of the total sample size of 426 samples provided by two separate testing centers, and the specificity of negative test results was more than 99%. “This can help healthcare professionals confirm whether a person suspected of carrying the new coronavirus is infected, usually within 15 minutes,” Roche said in a press release. In addition, it is a valuable preliminary screening method for people exposed to new coronavirus infection or high-risk environments. ” Roche called the test “affordable” but did not disclose pricing details. The company said it does not rely on technical laboratory equipment, which means it can be used in scenarios where rapid and large-scale testing may be required. Roche said the company intends to apply to the U.S. Food and Drug Administration for an emergency use license. By the end of September, Roche said, the test will be available in countries that recognize European CE certification. < / P > < p > the company said the test method needs to be operated by medical professionals, but its advantage is that it does not need to be operated in a clinical laboratory, thus shortening the time required to produce test results. “This method is very useful when decisions need to be made in a timely manner or when laboratory testing is not possible,” Roche said in a press release. It will help to quickly identify the infected, improve patient management, and make more effective use of medical resources. ” < / P > < p > the company said the test method will be launched by the end of this month, with 40 million tests per month, and hopes to double the detection capacity by the end of the year. “Especially in the coming flu season, knowing whether a person is infected with a new coronavirus or influenza is very important to ensure that treatment is directed in the right direction,” Roche chief executive Thomas schneick said in a statement. A new coronavirus detection program that allows healthcare professionals and patients to quickly know the infection is essential to curb the spread of the new coronavirus in the community Abbott, an American medical device company, announced that its new rapid detection method for coronavirus was granted emergency authorization by FDA last week. Abbott said the test costs about $5 and can get results in minutes. < / P > < p > however, FDA only approved this test for symptomatic patients within 7 days of symptom onset. However, U.S. Department of health and human services officials later clarified that under the guidance of local health officials, the test can be used for non label specific purposes to screen asymptomatic people. < / P > < p > as soon as this test method is authorized, the trump government has ordered at least 150 million test reagents, roughly equivalent to the company’s total supply in 2020. The purchase is part of an agreement worth more than $750 million. 08/17/2020